After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback